Yuhan Corporation to Supply 85 Billion Won Worth of Hepatitis C Treatment APIs to Gilead
by Jeong Donghoon
Published 27 Aug.2025 10:10(KST)
API supply contracts with Gilead total 170 billion won this month
HIV and hepatitis C treatment ingredients to be delivered
Yuhan Corporation will supply Gilead Sciences not only with active pharmaceutical ingredients (APIs) for HIV (Human Immunodeficiency Virus/AIDS) treatments, but also with APIs for hepatitis C (HCV) treatments. The combined value of the two contracts amounts to approximately 170 billion won.
On the 27th, Yuhan Corporation announced that it had signed a contract with Gilead to supply APIs for hepatitis C treatments worth 85 billion won. The contract amount is equivalent to 4.11% of last year's sales. The contract period runs from May 29, 2026, to May 31, 2027.
Previously, on the 20th, Yuhan Corporation entered into a contract with Gilead to supply APIs for HIV treatments. The value of this contract is approximately 84.27 billion won, and it will be effective from March 31, 2026, to February 26, 2027. As a result, Yuhan Corporation has secured a total of 169.2 billion won in API supply contracts with Gilead just this month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.